@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech
@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce
@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce
> Celgene ($CELG) added a big approval for Otezla, gaining the FDA's approval to market the drug for psoriasis. Story
> Vitae Pharmaceuticals ($VTAE) priced its IPO at $8 a share, well below its proposed range of $11 to $13 a share. Release
> Texas-based ZS Pharma ($ZSPH) says it garnered positive data for its second Phase III clinical trial of ZS-9 (sodium zirconium cyclosilicate), which has been in the clinic for hyperkalemia. Release
Medical Device News
@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev
@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce
@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2
@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce
> Little is known about the Sunshine Act site ahead of launch, AdvaMed says. Article
> FDA to weigh in on cybersecurity concerns. Report
Pharma News
@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma
@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce
> GlaxoSmithKline soon to name RBS chair Hampton as next chairman. Report
> Oh, what a tangled web of pharma M&A, starring Pfizer, Actavis, Allergan and Salix. Story
> Ackman threatens Allergan with lawsuit if Salix deal is sealed. Article
Drug Delivery News
> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item
> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report
> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story
> Titan Pharma trial of implant for addicts on track. Article
> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More
Diagnostics News
> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News
> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report
> Sequenom keeps prenatal Dx competition running with new positive data. Article
> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story
> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More
Pharma Marketing News
> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report
> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More
> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item
> Can copay coupons be kickbacks? HHS says yes. More
> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article